This offers an opportunity to regain β-cells destroyed by an autoimmune reaction leading to deficiency of endogenous insulin secretion (T1DM) and secondary abnormalities in the function of other pancreatic islet cells, such as abnormal glucagon release by α-cells. The gene discussed is INS; the disease is type 1 diabetes mellitus.